secwatch.observer — SEC 8-K summary
======================================

Issuer:     Better Therapeutics, Inc. (—)
CIK:        0001832415
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001193125-24-068672
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Better Therapeutics voluntarily delists from Nasdaq, entire board and top officers replaced by wind-down specialist
--------------------------------------------------------------------------------

- Nasdaq hearing March 14 led to voluntary delisting; trading suspended March 18, 2024.
- All seven directors resigned, including Chairman Frank Karbe, and CEO Karbe stepped down.
- CMO Dr. Mark Berman and CPO Kristyn Wynholds terminated from positions.
- Craig R. Jalbert appointed sole officer and director; annual compensation $33,333.
- Company intends to file Form 15 to suspend SEC reporting obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/0001193125-24-068672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832415/000119312524068672/d812144d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-068672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer